LAS VEGAS (MedPage Today) -- The tumor necrosis factor inhibitor etanercept (Enbrel) was more cost-effective for the treatment of rheumatoid arthritis than were two other biologic agents in this class, a budget impact analysis found. via MedPageToday.com - medical news plus CME for physicians Read More Here..
No comments:
Post a Comment